VU Research Portal

In vivo oxidised cholesterol in atherosclerosis

Stalenhoef, A.F.H.; Kleinveld, H.A.; Kosmeijer-Schuil, J.G.; Demacker, P.N.M.; Katan, M.B.

published in
Atherosclerosis
1993

document version
Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Stalenhoef, A. F. H., Kleinveld, H. A., Kosmeijer-Schuil, J. G., Demacker, P. N. M., & Katan, M. B. (1993). In vivo oxidised cholesterol in atherosclerosis. *Atherosclerosis*, 223(98), 113-4.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:
vuresearchportal.ub@vu.nl

ATHERO 04946

Letter to the Editors

In vivo oxidised cholesterol in atherosclerosis

Anton F.H. Stalenhoef^a, Henne A. Kleinveld^a, Truus G. Kosmeijer-Schuil^b,
Pierre N.M. Demacker^a and Martijn B. Katan^b

^aDepartment of Medicine, Division of General Internal Medicine, University Hospital Nijmegen and ^bDepartment of Human Nutrition, Wageningen Agricultural University, Wageningen (The Netherlands)

Key words: Oxidized cholesterol; Modified LDL; Atherosclerosis

Dear Editors,

Evidence has been increasing the last several years that oxidative modification of LDL may play an important role in the pathogenesis of atherosclerosis [1,2]. Further support for the oxidative modification hypothesis is provided by the recent report of Salonen et al. [3] who found that the titre of autoantibodies to malondialdehyde-modified LDL was an independent predictor of the progression of carotid atherosclerosis. Although there is little doubt about the specificity of these antibodies to artificially oxidised LDL [4], direct evidence that LDL oxidation actually takes place *in vivo* is scarce; most research on oxidation of LDL involves oxidisability *in vitro*. We have measured circulating cholesterol oxidation products in WHHL rabbits. Six-month-old rabbits

(mean ($\pm$ S.D.) serum cholesterol 18.3 ± 2.3 mmol/l, mean serum triglycerides 3.2 ± 0.9 mmol/l) were fed with either cholesterol-free control chow or chow mixed with the antioxidant probucol in a low dose (10 mg/kg per day). High doses of probucol are known to retard atherogenesis in these animals [5]. One control animal died during the study period. After 6 months of treatment blood was drawn into vacutainer tubes containing EDTA plus 10 mg of reduced glutathione, plasma was prepared immediately and 0.1 mg of the antioxidant butylated hydroxytoluene added per ml. This treatment effectively prevents oxidation *in vitro*: in plasma of 5 normal volunteers we found total oxysterol levels of $1.36 \mu\text{mol/l}$ at time 0 and $1.32 \mu\text{mol/l}$ after 6 month of storage at -80°C . Cholesterol oxidation products were determined by a modification of our previously described method [6].

The mean concentration of serum cholesterol was unaffected in the control animals (18.6 ± 1.3

Correspondence to: Dr. A.F.H. Stalenhoef, Department of Internal Medicine, University Hospital Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.

TABLE 1

PLASMA LEVELS OF OXYSTEROLS ($\mu\text{mol/l}$) IN 3 CONTROL AND 4 PROBUCOL-TREATED WHHL RABBITS (MEAN (S.D.))

	Control	Probucol	P
Total oxysterols	9.15 (1.33)	4.64 (0.58)	<0.01
7 α -Hydroxycholesterol	5.04 (0.33)	2.17 (0.64)	<0.001
5,6 α -Epoxycholestanol	0.78 (0.44)	0.39 (0.21)	NS
7 β -Hydroxycholesterol	0.69 (0.23)	0.54 (0.09)	NS
5 α -Cholestanetriol	0.88 (0.10)	0.55 (0.09)	<0.01
7-Ketocholesterol	1.41 (0.39)	0.84 (0.11)	<0.01
25-Hydroxycholesterol	0.35 (0.13)	0.15 (0.02)	<0.05

vs. 19.0 ± 1.9 mmol/l), whereas there was a slight decrease in the probucol treated animals (17.7 ± 2.4 vs. 14.2 ± 1.8 mmol/l). Ingestion of a low dose of probucol caused a 50% difference in the levels of circulating cholesterol oxidation products (oxysterols) (Table 1).

This study provides direct evidence that oxidised lipoproteins occur in vivo in the circulation and that administration of low doses of probucol can prevent oxidation to a large extent, explaining its anti-atherogenic effect in WHHL rabbits.

References

- 1 Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C., and Witztum, J.L., Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity, *N. Engl. J. Med.*, 320 (1989) 915.
- 2 Witztum, J.L. and Steinberg, D., Role of oxidized low density lipoprotein in atherogenesis, *J. Clin. Invest.*, 88 (1991) 1785.
- 3 Salonen J.T., Ylä-Herttuala, S., Yamamoto, R., Butler, S., Korpela, H., Salonen, R., Nyssönen, K., Palinski, W. and Witztum J.L., Autoantibody against oxidised LDL and the progression of carotid atherosclerosis, *Lancet*, 339 (1992) 883.
- 4 Editorial, Antibodies to oxidised LDL in atherosclerosis, *Lancet*, 339 (1992) 899.
- 5 Carew, T.E., Schwenke, D.C. and Steinberg, D., Anti-atherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit, *Proc. Natl. Acad. Sci. USA*, 84 (1987) 7725.
- 6 van de Bovenkamp P., Kosmeijer-Schuil, T.G. and Katan, M.B., Quantification of oxysterols in Dutch foods: Egg products and mixed diets, *Lipids*, 23 (1988) 1079.